Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 18;18(6):1146-1151.
doi: 10.18240/ijo.2025.06.22. eCollection 2025.

Therapeutic potential of artesunate in retinal diseases: from mechanism to clinical applications

Ying-Chao Xue  1   2 , Xiao-Long Liu  3 , Bo-Yu Liu  1   2 , Sheng-Xiang Zhang  1   2 , Qi-Hua Xu  1 , Ling-Dan Wu  1
Affiliations
Review

Therapeutic potential of artesunate in retinal diseases: from mechanism to clinical applications

Ying-Chao Xue et al. Int J Ophthalmol. .

Abstract

Artesunate is a derivative of artemisinin, and due to its high solubility, and it has a broader application in clinical settings. Extensive research has confirmed that artemisinin-based drugs show significant activities in anti-inflammatory, anti-tumor, anti-viral, and anti-angiogenesis aspects, suggesting that artesunate might have potential in treating retinal diseases. Currently, the etiology of most retinal diseases is not fully understood, and there is a lack of effective treatment methods. This paper summarized the research progress of artesunate in the treatment of retinal diseases, including retinoblastoma, choroidal melanoma, diabetic retinopathy, central retinal vein occlusion, proliferative retinopathy, and ocular neovascularization. In addition, the potential applications and future research directions of artesunate in the treatment of retinal diseases were also discussed.

Keywords: artesunate; choroidal melanoma; diabetic retinopathy; ocular neovascularization; proliferative vitreoretinopathy; retinal vein occlusion; retinoblastoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Xue YC, None; Liu XL, None; Liu BY, None; Zhang SX, None; Xu QH, None; Wu LD, None.

Figures

Figure 1
Figure 1. Progress in the therapeutic use of artesunate in fundus diseases
DR: Diabetic retinopathy; AMD: Age-related macular degeneration; PVR: Proliferative vitreoretinopathy; BRVO: Branch retinal vein occlusion; EMT: Epithelial-mesenchymal transition; VEGF: Vascular endothelial growth factor; VEGFR2: Vascular endothelial growth factor receptor 2; PDGFR: Platelet-derived growth factor receptor; VEGFA: Vascular endothelial growth factor A; AMPK/SIRT1: AMP-activated protein kinase/silent information regulator of transcription 1; TGF-β: Transforming growth factor-β; VE-cadherin: Vascular endothelial-cadherin; EphA2: Ephrin type-A receptor 2; PI3K/Akt: Phosphoinositide 3-kinase/protein kinase B.
See this image and copyright information in PMC

References

    1. Ma N, Zhang Z, Liao F, et al. The birth of artemisinin. Pharmacology & therapeutics. 2020;216:107658. - PubMed
    1. Wu TC, Feng HY, He MM, et al. Efficacy of artemisinin and its derivatives in animal models of type 2 diabetes mellitus: a systematic review and meta-analysis. Pharmacol Res. 2022;175:105994. - PubMed
    1. Chemaly RF, Hill JA, Voigt S, et al. In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review. Antiviral Res. 2019;163:50–58. - PubMed
    1. Zuo SL, Li Q, Liu X, et al. The potential therapeutic effects of artesunate on stroke and other central nervous system diseases. Biomed Res Int. 2016;2016:1489050. - PMC - PubMed
    1. Huang SH, Galaj E, Wang JF, et al. Repurposing antimalarial artesunate for the prophylactic treatment of depression: Evidence from preclinical research. Brain Behav. 2023;13(1):e2833. - PMC - PubMed

LinkOut - more resources